Bedrijfsoverzicht
Soren Acquisition Corp. is a special purpose acquisition company (SPAC) dedicated to executing a business combination with one or more target entities, specifically focusing on opportunities within the healthcare industry. The company operates within the Financial Services sector, categorized under the industry of Shell Companies, which implies its current existence is primarily a vehicle for future merger activity rather than active revenue generation. As of the latest available data, the company holds a market capitalization of $343.86M, while specific annual revenue and employee count metrics are not publicly disclosed in standard financial reports. This market cap indicates that the company possesses significant market value relative to its operational footprint, reflecting the premium investors place on its potential to identify and acquire high-value healthcare targets, whereas the lack of traditional revenue figures highlights its transitional status as a shell entity awaiting a definitive business combination.
Financiële gezondheid
The company reports a net income of $-249,627 for the trailing twelve months, while both revenue and EBITDA figures are currently listed as unavailable, a status typical for SPACs prior to a completed merger. The absence of reported revenue coupled with a negative net income reveals a cost structure where expenses, likely related to administrative overhead and operational maintenance of the shell structure, exceed any incidental income generated. Free cash flow data is not reported, suggesting that the company currently lacks the operational cash generation required for financial flexibility and relies entirely on capital raised during its initial public offering. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company is not yet generating profitable operations from its core business activities. Regarding liquidity and leverage, the company holds a debt obligation of $13,320 against a cash position that is not explicitly quantified in the provided data, yet the debt-to-equity ratio stands at 153.62, pointing to a highly leveraged balance sheet relative to its equity base. The current ratio is 0.05, a figure that signals severe short-term liquidity constraints, indicating that the company's current assets are insufficient to cover its current liabilities without external financing. Return on Equity and Return on Assets are both unavailable, reflecting the inability to calculate these return metrics due to the lack of positive earnings and standard asset utilization typical of a pre-merger SPAC.
Waarderingsbeoordeling
Trailing P/E and forward P/E ratios are both listed as N/A, which implies that the company does not have a positive earnings base to support a traditional price-to-earnings valuation, nor is there forward guidance available to assess an earnings trajectory. The price-to-book ratio is recorded at -1237.50, a negative figure that indicates the market is pricing the company based on its liquidation value or the value of its trust assets rather than its tangible book value, often resulting in a significant premium or discount depending on the trust account balance. Price-to-sales and EV/EBITDA metrics are also unavailable, suggesting that alternative valuation methods relying on revenue multiples or enterprise value relative to cash flows are not applicable at this stage of the company's lifecycle. The stock has traded between a 52-week high of $10.88 and a 52-week low of $9.81, and the current price position relative to this range must be interpreted within the context of market sentiment regarding SPACs, though the exact current price is not explicitly stated in the provided facts. The beta value is listed as N/A, meaning that the stock's volatility relative to the broader market cannot be quantified using historical price movements, likely due to the low liquidity or limited trading volume often associated with such securities.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both reported as N/A, as the company has not yet generated sustained revenue streams to calculate growth rates from a prior period. Since the company does not pay a dividend and has no dividend yield or payout ratio, it follows the standard SPAC model of reinvesting all available capital into identifying and closing a merger with a healthcare target rather than distributing income to shareholders. The overall growth and income profile is currently characterized by a lack of historical performance data, with the company's primary objective being the execution of a business combination that will subsequently define its growth trajectory and income-generating capabilities.